Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?

Argenx reported Q2 revenue growth of 60% YoY (and +17% sequentially) alongside earnings of $472M, nearly doubling year over year as operating margins expand. The company expects multiple pivotal readouts through 2H 2027, including Phase 3 empasiprubart results for MMN in Q4 2026 and additional late-stage data for ITP (1H 2027) and Sjogren’s (2H 2027), while citing large expansion runway given only ~20% of gMG patients use novel biologics. Wall Street sentiment is constructive: 20 of 23 analysts rate the stock a buy/strong buy, implying ~14% upside to the 12-month price target despite a 37.5x forward earnings valuation.

Analysis

ARGX looks like a quality-growth story with a surprisingly long runway, but the market is increasingly paying for that durability upfront. The core mechanism is not just revenue growth; it is mix improvement and operating leverage as a single franchise moves from “launch” to “standard of care” in a still-underpenetrated autoimmune niche. That matters because it creates a self-reinforcing loop: better sales density funds more trial activity, which lowers the probability of a pipeline valuation reset.

The main winners are ARGX and, secondarily, HALO as a toll-road beneficiary of Hytrulo adoption; the bigger second-order effect is on competitors in FcRn/autoimmune biologics who will need to spend more aggressively on trials, reimbursement, and physician conversion. If self-administered or less burdensome regimens keep taking share from infusion-center dependent care, hospital buy-and-bill economics weaken and payer pressure rises on older therapies. Over 6-18 months, the real question is whether the franchise expands fast enough to justify a premium multiple once the market stops treating every pipeline readout as free optionality.

Risk is binary and timing-sensitive: the next 1-3 quarters are mostly about sentiment and valuation, while the Q4 2026 through 2027 readout cluster determines whether ARGX becomes a multi-product platform or a single-asset story in disguise. The contrarian risk is that consensus is overestimating how much of the growth is durable versus how much is simply early-share capture in a narrow, addressable pool. Any disappointment in MMN, ITP, or CIDP would likely compress the multiple faster than fundamentals deteriorate, because the stock is already priced for continued clinical execution.

Key Decisions for Investors

• Maintain a core long ARGX, but prefer entering on 5-10% post-news drawdowns rather than chasing strength; 6-12 month thesis is durable growth plus multiple support, but valuation leaves limited margin for error.
• Pair trade: long ARGX / short XBI for 3-6 months to isolate idiosyncratic clinical and commercial execution from broad biotech beta; this is cleaner than a naked long if sector risk-off returns.
• Treat HALO as a secondary beneficiary, not the main event; only add on evidence of continued Hytrulo script acceleration, because the royalty/toll-road upside is real but smaller and slower than the market often assumes.
• Set a downside alert on ARGX if any pivotal readout misses or if management guidance implies adoption is stalling below the current penetration trajectory; that would be the fastest path to multiple compression.
• If you want optionality into the 2027 catalyst cluster, consider a 12-18 month call spread financed on weakness rather than outright stock, since the stock’s premium valuation makes timing risk the dominant variable.